Next generation immunoassays for groundbreaking biomarker research
| Reference number | |
| Coordinator | Olink AB |
| Funding from Vinnova | SEK 3 500 000 |
| Project duration | September 2011 - June 2013 |
| Status | Completed |
Important results from the project
The aim for Olink with this project was to create the next generation technology platform for multiplex biomarker detection, mainly as a tool to be used within biomarker research. Two 96-plex panels were developed to measure 92 biomarkers in 1 micro liter of blood plasma. The project has resulted in commercialization of one panel which measures 92 cancer markers and a second panel, soon to be released, which measures 92 cardiovascular markers.
Expected long term effects
It was expected that the multiplex panels developed within the scope of this project to be at the forefront of the field of biomarker discovery, with regards to amount of generated data, time for analysis, sample consumption and cost per data point. The first product which was release the first of March this year (Proseek Multiplex Oncology I) meets these expectations well, and has even resulted in that Olinks focus has shifted toward developing new multiplex panels.
Approach and implementation
The panel development were divided into six stages: (1) Design of sequence system and protocol optimization (generic for all panels); (2) Biomarker selection; (3) Conjugation and evaluation of proximity probes; (4) Production transfer and (5) Validation and verification to establish fulfillment of specifications and the measurement systems performance parameters. This setup proved to work well, but we learned that stage (2) should be executed very thoroughly and thus much time will be saved.